SILu (TM) Prot MAPK3Mitogen activé pr

Code: msst0019-10ug D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

MAPK3, the first mammalian MAPK to be characterized and cloned, is commonly expressed in most tissues and is activated through the small guanosine tri...


en savoir plus

Votre prix
$740.95 10UG
$889.14 inc. VAT

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

MAPK3, the first mammalian MAPK to be characterized and cloned, is commonly expressed in most tissues and is activated through the small guanosine triphosphatase Ras and sequential activation of the protein kinases Raf and MEK upon stimulation of cells with a broad range of extracellular signals. Erk was suggested to be a good marker for estradiol and tamoxifen effects. Alzheimer’;s disease’;s Erk1 and Erk2 index values were inversely correlated with disease duration, suggesting maximal efficacy for early diagnosis. In addition, differential Erk1 and Erk2 phosphorylation, could have important clinical utility for providing increased certainty in the positive diagnosis of AD, particularly in the early phase of disease progression.

General description

SILu Prot MAPK3 is a recombinant, stable isotope-labeled human MAPK3 which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of MAPK3 in mass-spectrometry. SILu Prot MAPK3 is a monomer of 399 amino acids (including N-terminal polyhistidine and flag tags), with a molecular weight of ~45.5 kDa.

Legal Information

SILu is a trademark of Sigma-Aldrich Co. LLC

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.

Physical form

Supplied as a 0.1 mg/mL solution of 20mM sodium phosphate, pH 8.0, 1M NaCl.

Sequence

MDYKDDDDKGHHHHHHHHGGQAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP

assay≥95% (SDS-PAGE)
formliquid
potency≥98% Heavy amino acids incorporation efficiency by MS
Quality Level200
recombinantexpressed in HEK 293 cells
storage temp.−20°C
suitabilitysuitable for mass spectrometry (standard)
tagHis tagged
UniProt accession no.P27361
Ce produit répond aux critères suivants: